Clinical Trial: A prospective, multicenter, randomized, evaluator-blind, positive-controlled, noninferiority clinical study (IIT) to evaluate the efficacy and safety of follicle-stimulating hormone αN01 (Shengnuowa) in assisted reproduction in patients with ovarian hyporesponsiveness (POR). (China)

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, multicenter, randomized, evaluator-blind, positive-controlled, noninferiority clinical study (IIT) to evaluate the efficacy and safety of follicle-stimulating hormone αN01 (Shengnuowa) in assisted reproduction in patients with ovarian hyporesponsiveness (POR).'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130601

Registration Time: 2026/08/21

Type: Interventional study

Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338692

Publish...